Синдром раздраженного кишечника и функциональная диспепсия: механизмы коморбидности

1. Tack J. Rome V: Disorders of gut-brain interaction. Gastroenterology. 2026;170(6):1083–416.

URL: https://www.gastrojournal.org/issue/S0016-5085(25)X0007-X (date of access – 21.04.2026).

2. Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114.e3.

PMID: 32294476. https://doi.org/10.1053/j.gastro.2020.04.014

3. Wu X, Wang J, Ye Z, Wang J, Liao X, Liv M, Svn Z. Risk of colorectal cancer in patients with irritable bowel syndrome: A meta-analysis of population-based observational studies. Front Med (Lausanne). 2022;9:819122.

PMID: 35308554. https://doi.org/10.3389/fmed.2022.819122

4. Chuah KH, Beh KH, Mahamad Rappek NA, Mahadeva S. The epidemiology and quality of life of functional gastrointestinal disorders according to Rome III vs Rome IV criteria: A cross-sectional study in primary care. J Dig Dis. 2021;22(3):159–66.

PMID: 33595169. https://doi.org/10.1111/1751-2980.12975

5. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010;8(5):401–9.

PMID: 19631762. https://doi.org/10.1016/j.cgh.2009.07.020

6. Barberio B, Yiannakou Y, Houghton LA, Black CJ, Savarino EV, Ford AC. Overlap of Rome IV irritable bowel syndrome and functional dyspepsia and effect on natural history: A longitudinal follow-up study. Clin Gastroenterol Hepatol. 2022;20(2):e89–e101.

PMID: 33839276. https://doi.org/10.1016/j.cgh.2021.04.011

7. Андреев Д.Н., Бордин Д.С., Вьючнова Е.С., Лебедева Е.Г., Дичева Д.Т., Умярова Р.М., Маев И.В. Частота сочетания функциональной диспепсии и синдрома раздраженного кишечника: метаанализ исследований с использованием римских критериев III–IV пересмотра. Терапевтический архив. 2022;94(9):1099–1108. (Andreev DN, Bordin DS, Vyuchnova ES, Lebedeva EG, Dicheva DT, Umyarova RM, Maev IV. Prevalence of combination of functional dyspepsia and irritable bowel syndrome: a meta-analysis of studies using the Rome III–IV Criteria. Terapevticheskiy arkhiv = Therapeutic Archive. 2022;94(9):1099–1108 (In Russ.)).

EDN: VFCRAL. https://doi.org/10.26442/00403660.2022.09.201849

8. Ливзан М.А., Осипенко М.Ф. Синдром перекреста функциональных заболеваний пищеварительного тракта. РМЖ. 2012;20(15):768–770. (Livzan MA, Osipenko MF. Syndrome of overlap of functional diseases of the digestive tract. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2012;20(15):768–770 (In Russ.)). EDN: PASLVJ.

9. Mukhtar K, Nawaz H, Abid S. Functional gastrointestinal disorders and gut-brain axis: What does the future hold? World J Gastroenterol. 2019;25(5):552–66.

PMID: 30774271. PMCID: PMC6371005. https://doi.org/10.3748/wjg.v25.i5.552

10. Chen C, Zhang DY, Chen S, Huang S, Zeng F, Li D et al. Prevalence, types, and risk factors of functional gastrointestinal diseases in Hainan Province, China. Sci Rep. 2024;14(1):4553.

PMID: 38402323. PMCID: PMC10894239. https://doi.org/10.1038/s41598-024-55363-4

11. Amerikanou C, Kleftaki SA, Valsamidou E, Chroni E, Biagki T, Sigala D et al. Food, dietary patterns, or is eating behavior to blame? Analyzing the nutritional aspects of functional dyspepsia. Nutrients. 2023;15(6):1544.

PMID: 36986274. PMCID: PMC10059716. https://doi.org/10.3390/nu15061544

12. Banker H, Goel A, Kumawat S, Anamika F, Aggarwal K, Clarke K, Jain R. Cognitive impairment in IBS: A narrative overview. J Gastrointestin Liver Dis. 2025;34(1):122–27.

PMID: 40153810. https://doi.org/10.15403/jgld-5800

13. Lee A, Lee JY, Jung SW, Shin SY, Ryu HS, Jang SH et al. (Brain-gut-microbiota axis. Korean J Gastroenterol. 2023;81(4):145–53 (In Korean)).

PMID: 37096434. PMCID: PMC12094008. https://doi.org/10.4166/kjg.2023.028

14. Shin A, Preidis GA, Shulman R, Kashyap PC. The gut microbiome in adult and pediatric functional gastrointestinal disorders. Clin Gastroenterol Hepatol. 2019;17(2):256–74.

PMID: 30153517. PMCID: PMC6314902. https://doi.org/10.1016/j.cgh.2018.08.054

15. Aggeletopoulou I, Triantos C. Microbiome shifts and their impact on gut physiology in irritable bowel syndrome. Int J Mol Sci. 2024;25(22):12395.

PMID: 39596460. PMCID: PMC11594715. https://doi.org/10.3390/ijms252212395

16. Duan R, Zhu S, Wang B, Duan L. Alterations of gut microbiota in patients with irritable bowel syndrome based on 16S rRNA-targeted sequencing: A systematic review. Clin Transl Gastroenterol. 2019;10(2):e00012.

PMID: 30829919. PMCID: PMC6407812. https://doi.org/10.14309/ctg.0000000000000012

17. Ghoshal U, Shukla R, Srivastava D, Ghoshal UC. Irritable bowel syndrome, particularly the constipation-predominant form, involves an increase in Methanobrevibacter smithii, which is associated with higher methane production. Gut Liver. 2016;10(6):932–38.

PMID: 27458176. PMCID: PMC5087933. https://doi.org/10.5009/gnl15588

18. Ghoshal UC, Srivastava D, Misra A. A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study. Indian J Gastroenterol. 2018;37(5):416–23.

PMID: 30406392. https://doi.org/10.1007/s12664-018-0901-6

19. Villanueva-Millan MJ, Leite G, Wang J, Morales W, Parodi G, Pimentel ML et al. Methanogens and hydrogen sulfide producing bacteria guide distinct gut microbe profiles and irritable bowel syndrome subtypes. Am J Gastroenterol. 2022;117(12):2055–66.

PMID: 36114762. PMCID: PMC9722381. https://doi.org/10.14309/ajg.0000000000001997

20. Su Q, Tun HM, Liu Q, Yeoh YK, Mak JWY, Chan FK, Ng SC. Gut microbiome signatures reflect different subtypes of irritable bowel syndrome. Gut Microbes. 2023;15(1):2157697.

PMID: 36573834. PMCID: PMC9809927. https://doi.org/10.1080/19490976.2022.2157697

21. Teige ES, Sortvik U, Lied GA. A systematic review: Fecal bacterial profile in patients with irritable bowel syndrome analyzed with the GA-Map dysbiosis test based on the 16S rRNA gene of bacterial species or groups. Clin Exp Gastroenterol. 2024;17:109–20.

PMID: 38646157. PMCID: PMC11032674. https://doi.org/10.2147/CEG.S451675

22. Tap J, Derrien M, Tornblom H, Brazeilles R, Cools-Portier S, Dore J et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152(1):111–23.e8.

PMID: 27725146. https://doi.org/10.1053/j.gastro.2016.09.049

23. Zhong L, Shanahan ER, Raj A, Koloski NA, Fletcher L, Morrison M et al. Dyspepsia and the microbiome: Time to focus on the small intestine. Gut. 2017;66(6):1168–69.

PMID: 27489239. https://doi.org/10.1136/gutjnl-2016-312574

24. Fukui A, Takagi T, Naito Y, Inoue R, Kashiwagi S, Mizushima K et al. Higher levels of streptococcus in upper gastrointestinal mucosa associated with symptoms in patients with functional dyspepsia. Digestion 2020;101(1):38–45.

PMID: 31752012. https://doi.org/10.1159/000504090

25. Shanahan ER, Kang S, Staudacher H, Shah A, Do A, Burns G et al. Alterations to the duodenal microbiota are linked to gastric emptying and symptoms in functional dyspepsia. Gut. 2023;72(5):929–38.

PMID: 36167662. https://doi.org/10.1136/gutjnl-2021-326158

26. Jin X, Xu K, Wu J, Yang C, Bao J, Du et al. The causality between gut microbiota and functional dyspepsia: A two-sample Mendelian randomization analysis. Medicine (Baltimore). 2024;103(43):e40180.

PMID: 39470569. PMCID: PMC11521013. https://doi.org/10.1097/MD.0000000000040180

27. Гаус О.В., Ливзан М.А. Модуляция микробиоты кишечника как ведущий фактор патогенеза формирования фенотипов синдрома раздраженного кишечника. РМЖ. 2023;(5):12–19 (Gaus OV, Livzan MA. Gut microbiota modulation as a leading factor in the pathogenesis of the IBS phenotypes. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2023;(5):12–19 (In Russ.)). EDN: HHRIJP.

28. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91–119.

PMID: 24388214. https://doi.org/10.1016/B978-0-12-800100-4.00003-9

29. Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne). 2020;11:25.

PMID: 32082260. PMCID: PMC7005631. https://doi.org/10.3389/fendo.2020.00025

30. Natarajan N, Pluznick JL. From microbe to man: The role of microbial short chain fatty acid metabolites in host cell biology. Am J Physiol Cell Physiol. 2014;307(11):C979–C985.

PMID: 25273884. PMCID: PMC5243208. https://doi.org/10.1152/ajpcell.00228.2014

31. Karaki S, Mitsui R, Hayashi H, Kato I, Sugiya H, Iwanaga T et al. Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell Tissue Res. 2006;324(3):353–60.

PMID: 16453106. https://doi.org/10.1007/s00441-005-0140-x

32. Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauchi S et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A. 2011;108(19):8030–35.

PMID: 21518883. PMCID: PMC3093469. https://doi.org/10.1073/pnas.1016088108

33. He M, Wei W, Zhang Y, Xiang Z, Peng D, Kasimumali A, Rong S. Gut microbial metabolites SCFAs and chronic kidney disease. J Transl Med. 2024;22(1):172.

PMID: 38369469. PMCID: PMC10874542. https://doi.org/10.1186/s12967-024-04974-6

34. Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?. EBioMedicine. 2021;66:103293.

PMID: 33813134. PMCID: PMC8047503. https://doi.org/10.1016/j.ebiom.2021.103293

35. Ju X, Jiang Z, Ma J, Yang D. Changes in fecal short-chain fatty acids in IBS patients and effects of different interventions: A systematic review and meta-analysis. Nutrients. 2024;16(11):1727.

PMID: 38892659. PMCID: PMC11174707. https://doi.org/10.3390/nu16111727

36. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(5):512–e115.

PMID: 19903265. https://doi.org/10.1111/j.1365-2982.2009.01427.x

37. Vernia P, Latella G, Magliocca FM, Mancuso G, Caprilli R. Seeking clues for a positive diagnosis of the irritable bowel syndrome. Eur J Clin Invest. 1987;17(3):189–93.

PMID: 3113963. https://doi.org/10.1111/j.1365-2362.1987.tb01234.x

38. Kopecny J, Simunek J. Cellulolytic bacteria in human gut and irritable bowel syndrom. Acta Vet Brno. 2002;71(4):421–27.

https://doi.org/10.2754/avb200271040421

39. Cherbut C, Ferrier L, Roze C, Anini Y, Blottière H, Lecannu G, Galmiche JP. Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat. Am J Physiol. 1998;275(6):1415–22.

PMID: 9843779. https://doi.org/10.1152/ajpgi.1998.275.6.G1415

40. Grider JR, Piland BE. The peristaltic reflex induced by short-chain fatty acids is mediated by sequential release of 5-HT and neuronal CGRP but not BDNF. Am J Physiol Gastrointest Liver Physiol. 2007;292(1):429–37.

PMID: 16973914. https://doi.org/10.1152/ajpgi.00376.2006

41. Cuche G, Cuber JC, Malbert CH. Ileal short-chain fatty acids inhibit gastric motility by a humoral pathway. Am J Physiol Gastrointest Liver Physiol. 2000;279(5):G925–G930.

PMID: 11052989. https://doi.org/10.1152/ajpgi.2000.279.5.G925

42. Ropert A, Cherbut C, Roze C, Le Quellec A, Holst JJ, Fu-Cheng X et al. Colonic fermentation and proximal gastric tone in humans. Gastroenterology. 1996;111(2):289–96.

PMID: 8690193. https://doi.org/10.1053/gast.1996.v111.pm8690193

43. Moonwiriyakit A, Pathomthongtaweechai N, Steinhagen PR, Chantawichitwong P, Satianrapapong W, Pongkorpsakol P. Tight junctions: From molecules to gastrointestinal diseases. Tissue Barriers. 2023;11(2):2077620.

PMID: 35621376. PMCID: PMC10161963. https://doi.org/10.1080/21688370.2022.2077620

44. Ливзан М.А., Гаус О.В. Содержание фекального зонулина – биомаркер синдрома кишечной проницаемости у больных синдромом раздраженного кишечника (обзор и результаты пилотного исследования). Доказательная гастроэнтерология. 2021;10(3):47–55. (Livzan MA, Gaus OV. Fecal zonulin as a biomarker of increased intestinal permeability in patients with irritable bowel syndrome (narrative review and pilot study results). Dokazatel’naya gastroenterologiya = Russian Journal of Evidence-Based Gastroenterology. 2021;10(3):47–55 (In Russ.)).

EDN: HRUNEM. https://doi.org/10.17116/dokgastro20211003147

45. Vanheel H, Vicario M, Vanuytsel T, Van Oudenhove L, Martinez C, Keita AV et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63(2):262–71.

PMID: 23474421. https://doi.org/10.1136/gutjnl-2012-303857

46. Nojkov B, Zhou SY, Dolan RD, Davis EM, Appelman HD, Guo X et al. Evidence of duodenal epithelial barrier impairment and increased pyroptosis in patients with functional dyspepsia on confocal laser endomicroscopy and “ex vivo” mucosa analysis. Am J Gastroenterol. 2020;115(11):1891–901.

PMID: 33156108. PMCID: PMC8409129. https://doi.org/10.14309/ajg.0000000000000827

47. Wang Z, Hao M, Wu L, He Y, Sun X. Mast cells disrupt the duodenal mucosal integrity: Implications for the mechanisms of barrier dysfunction in functional dyspepsia. Scand J Gastroenterol. 2023;58(5):460–70.

PMID: 36345966. https://doi.org/10.1080/00365521.2022.2141075

48. Puthanmadhom Narayanan S, O’Brien DR, Sharma M, Smyrk TC, Graham RP, Grover M, Bharucha AE. Duodenal mucosal barrier in functional dyspepsia. Clin Gastroenterol Hepatol. 2022;20(5):1019–28.e3.

PMID: 34607017. PMCID: PMC8975906. https://doi.org/10.1016/j.cgh.2021.09.029

49. Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58(2):196–201.

PMID: 18824556. https://doi.org/10.1136/gut.2007.140806

50. Awad K, Barmeyer C, Bojarski C, Nagel O, Lee IM, Schweiger MR et al. Epithelial barrier dysfunction in diarrhea-predominant irritable bowel syndrome (IBS-D) via downregulation of claudin-1. Cells. 2023;12(24):2846.

PMID: 38132165. PMCID: PMC10741936. https://doi.org/10.3390/cells12242846

51. Гаус О.В., Ливзан М.А. При синдроме раздраженной кишки уровень зонулина ассоциирован с уровнями кортизола, дофамина и серотонина. Экспериментальная и клиническая гастроэнтерология. 2023;(4):37–48. (Gaus OV, Livzan MA. Zonulin levels are associated with cortisol, dopamine, and serotonin levels in irritable bowel syndrome. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2023;(4):37–48 (In Russ.)).

EDN: JIKATQ. https://doi.org/10.31146/1682-8658-ecg-212-4-37-48

52. Prospero L, Riezzo G, Linsalata M, Orlando A, D’Attoma B, Di Masi M et al. Somatization in patients with predominant diarrhoea irritable bowel syndrome: The role of the intestinal barrier function and integrity. BMC Gastroenterol. 2021;21(1):235.

PMID: 34022802. PMCID: PMC8141183. https://doi.org/10.1186/s12876-021-01820-7

53. Hanning N, Edwinson AL, Ceuleers H, Peters SA, De Man JG, Hassett LC et al. Intestinal barrier dysfunction in irritable bowel syndrome: A systematic review. Therap Adv Gastroenterol. 2021;14:1756284821993586.

PMID: 33717210. PMCID: PMC7925957. https://doi.org/10.1177/1756284821993586

54. Di Nardo G, Cremon C, Staiano A, Stanghellini V, Borrelli O, Strisciuglio C et al.; Neurogastroenterology Study Group of the Italian Society of Pediatric Gastroenterology Hepatology, Nutrition (SIGENP). Role of inflammation in pediatric irritable bowel syndrome. Neurogastroenterol Motil. 2023;35(3):e14365.

PMID: 35340083. https://doi.org/10.1111/nmo.14365

55. Spiller RC, Jenkins D, Thornley JP. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804–11.

PMID: 11076879. PMCID: PMC1728147. https://doi.org/10.1136/gut.47.6.804

56. Kindt S, Tertychnyy A, de Hertogh G, Geboes K, Tack J. Intestinal immune activation in presumed post-infectious functional dyspepsia. Neurogastroenterol Motil. 2009;21(8):832–e56.

PMID: 19460107. https://doi.org/10.1111/j.1365-2982.2009.01299.x

57. Salvo-Romero E, Martínez C, Lobo B, Rodino-Janeiro BK, Pigrau M, Sanchez-Chardi AD et al. Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in diarrhea-predominant irritable bowel syndrome. Sci Rep. 2020;10(1):20706.

PMID: 33244004. PMCID: PMC7692489. https://doi.org/10.1038/s41598-020-77176-x

58. Jarbrink-Sehgal ME, Sparkman J, Damron A, Walker MM, Green LK, Rosen DG et al. Functional dyspepsia and duodenal eosinophil count and degranulation: A multiethnic US veteran cohort study. Dig Dis Sci. 2021;66(10):3482–89.

PMID: 33185786. https://doi.org/10.1007/s10620-020-06689-2

59. Taki M, Oshima T, Li M, Sei H, Tozawa K, Tomita T et al. Duodenal low-grade inflammation and expression of tight junction proteins in functional dyspepsia. Neurogastroenterol Motil. 2019;31(10):e13576.

PMID: 30790378. https://doi.org/10.1111/nmo.13576

60. Shah A, Fairlie T, Brown G, Jones MP, Eslick GD, Duncanson K et al. Duodenal eosinophils and mast cells in functional dyspepsia: A systematic review and meta-analysis of case-control studies. Clin Gastroenterol Hepatol. 2022;20(10):2229–42.e29.

PMID: 35123088. https://doi.org/10.1016/j.cgh.2022.01.014

61. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693–702.

PMID: 14988823. https://doi.org/10.1053/j.gastro.2003.11.055

62. Walker MM, Aggarwal KR, Shim LS, Bassan M, Kalantar JS, Weltman MD et al. Duodenal eosinophilia and early satiety in functional dyspepsia: Confirmation of a positive association in an Australian cohort. J Gastroenterol Hepatol. 2014;29(3):474–79.

PMID: 24304041. https://doi.org/10.1111/jgh.12419

63. Barreyro FJ, Caronia MV, Elizondo K, Sanchez N, Jorda G, Schneider A, Zapata PD. Clinical implications of low-grade duodenal eosinophilia in functional dyspepsia: A prospective real-life study. J Clin Gastroenterol. 2023;57(4):362–69.

PMID: 36730183 https://doi.org/10.1097/MCG.0000000000001812

64. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203–9.

PMID: 25830558. PMCID: PMC4367209.

65. Drossman DA, Hasler WL. Rome IV – functional GI disorders: Disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257–61.

PMID: 27147121. https://doi.org/10.1053/j.gastro.2016.03.035

66. El-Salhy M, Gundersen D, Hatlebakk JG, Gilja OH, Hausken T. Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Regul Pept. 2014;188:60–65.

PMID: 24316398. https://doi.org/10.1016/j.regpep.2013.11.005

67. El-Salhy M, Lillebo E, Reinemo A, Salmelid L. Ghrelin in patients with irritable bowel syndrome. Int J Mol Med. 2009;23(6):703–7.

PMID: 19424595. https://doi.org/10.3892/ijmm_00000183

68. Shindo T, Futagami S, Hiratsuka T, Horie A, Hamamoto T, Ueki N et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion. 2009;79(2):65–72.

PMID: 19246923. https://doi.org/10.1159/000205740

69. Kim YS, Lee JS, Lee TH, Cho JY, Kim JO, Kim WJ et al. Plasma levels of acylated ghrelin in patients with functional dyspepsia. World J Gastroenterol. 2012;18(18):2231–37.

PMID: 22611317. PMCID: PMC3351774. https://doi.org/10.3748/wjg.v18.i18.2231

70. Mawe GM, Hoffman JM. Serotonin signalling in the gut – functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10(8):473–86.

PMID: 23797870. PMCID: PMC4048923. https://doi.org/10.1038/nrgastro.2013.105

71. Racke K, Reimann A, Schwörer H, Kilbinger H. Regulation of 5-HT release from enterochromaffin cells. Behav Brain Res. 1996;73(1–2):83–87.

PMID: 8788482. https://doi.org/10.1016/0166-4328(96)00075-7

72. Latorre E, Layunta E, Grasa L, Castro M, Pardo J, Gomollon F et al. Intestinal serotonin transporter inhibition by Toll-like receptor 2 activation. A feedback modulation. PLoS One. 2016;11(12):e0169303.

PMID: 28033388. PMCID: PMC5199115. https://doi.org/10.1371/journal.pone.0169303

73. Hansen MB. Neurohumoral control of gastrointestinal motility. Physiol Res 2003;52(1):1–30. PMID: 12625803.

74. Gros M, Gros B, Mesonero JE, Latorre E. Neurotransmitter dysfunction in irritable bowel syndrome: Emerging approaches for management. J Clin Med. 2021;10(15):3429.

PMID: 34362210. PMCID: PMC8347293. https://doi.org/10.3390/jcm10153429

75. Cheung CK, Lee YY, Chan Y, Cheong PK, Law WT, Lee SF et al. Decreased basal and postprandial plasma serotonin levels in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2013;11(9):1125–29.

PMID: 23591288. https://doi.org/10.1016/j.cgh.2013.03.026

76. Wisniewska-Jarosinska M, Harasiuk A, Klupinska G, Smigielski J, Stec-Michalska K, Chojnacki C. Diagnostic value of measuring serum serotonin and urinary 5-hydroxyindoleacetic acid concentration in the diagnosis of functional dyspepsia. Gastroenterology Review / Przegląd Gastroenterologiczny. 2010;5(5):285–91.

https://doi.org/10.5114/pg.2010.17266

77. Chojnacki C, Błonska A, Kaczka A, Chojnacki J, Stępien A, Gąsiorowska A. Evaluation of serotonin and dopamine secretion and metabolism in patients with irritable bowel syndrome. Pol Arch Intern Med. 2018;128(11):711–13.

PMID: 30398468 https://doi.org/10.20452/pamw.4364

78. Thijssen AY, Mujagic Z, Jonkers DM, Ludidi S, Keszthelyi D, Hesselink MA et al. Alterations in serotonin metabolism in the irritable bowel syndrome. Aliment Pharmacol Ther. 2016;43(2):272–82.

PMID: 26538292. https://doi.org/10.1111/apt.13459

79. Chojnacki C, Błonska A, Konrad P, Chojnacki M, Podogrocki M, Poplawski T. Changes in tryptophan metabolism on serotonin and kynurenine pathways in patients with irritable bowel syndrome. Nutrients. 2023;15(5):1262.

PMID: 36904262 PMCID: PMC10005076 https://doi.org/10.3390/nu15051262